Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-25-076281
Filing Date
2025-08-11
Accepted
2025-08-11 18:56:36
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 22488
2 EXHIBIT 99.1 tm2523148d1_ex99-1.htm EX-99.1 62235
3 EXHIBIT 99.2 tm2523148d1_ex99-2.htm EX-99.2 63075
  Complete submission text file 0001104659-25-076281.txt   149760
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713 248-681-9815
Opus Genetics, Inc. (Subject) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-79996 | Film No.: 251203445
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1751 RIVER RUN, SUITE 400 FORT WORTH TX 76107
Business Address 1751 RIVER RUN, SUITE 400 FORT WORTH TX 76107 817.984.9197
BIOS Fund III, LP (Filed by) CIK: 0001791917 (see all company filings)

EIN.: 843385883 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G